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1. Introduction  
Gastric cancer is one of the most frequent malignant tumors worldwide. It is known to have 
a poor prognosis leading to more than 600.000 fatalities every year. This dilemma is caused 
mainly by the late onset of clinical symptoms. Thus, when gastric cancer is diagnosed, more 
than 50% of patients cannot be cured. 
Even in those cases where cure by surgery can be achieved, the prognosis is poor due to the 
high incidence of early recurrence of the primary tumor as well as the development of 
metachronous metastases. The attempt to improve survival by extended surgical 
procedures, such as extensive lymph node removal did not have a significant impact on 
survival leading medical professionals to regard advanced gastric cancer as a systemic 
rather than a locally confined disease. Therefore, over the last two decades the importance of 
chemotherapy as a part of the curative treatment strategy was became more evident. The 
findings of molecular research show that gastric cancer has a very heterogenous biology 
with a broad variety of signalling pathways and chromosomal imbalances involved. With 
the growing insight into the molecular biology of gastric cancer it became clear that every 
single gastric cancer has to be regarded as an individual entity which can change its 
molecular behavior over time. This chapter presents the current knowledge of the molecular 
profile of gastric cancer. The most important basic signalling pathways that are known to 
play critical roles in the development as well as the progression of gastric cancer are 
discussed. Furthermore, the currently available molecular targets and their clinical relevance 
are reviewed in this chapter. 
2. Chromosomal imbalances in gastric cancer 
To date, the TNM system and the classification according to Lauren are the “gold standard” 
tools to predict survival and to define the treatment strategy in patients with gastric cancer. 
However, there is a wide range of clinical outcomes in patients with similar TNM stages. 
Therefore, it seems to be important to improve the characterization of gastric cancer by 
using molecular criteria [1].  
The development as well as the progression of gastric cancer is the result based on the 
interplay between the host genetic profile and the environment. The precise transfer of 
genetic information requires accurate replication, DNA mismatch repair and the segregation 
of replicated DNA strands. Whereas an impaired replication is not compatible with cellular 
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survival, the uneven distribution of chromosomes in tumor cells is termed aneuploidia and 
can be frequently observed in gastric cancer tissue. Defects in the mismatch repair system 
can gradually lead to chromosomal imbalances. Functional losses of MLH1 and MSH2 are 
known to cause multiple somatic mutations which may present microsatellite instability and 
may lead to tumor formation at multiple locations at a younger age in the colon /rectum 
(Lynch syndrome). Most frequently, the hypermethylation of CpG islands in the promoter 
region of these mismatch repair genes is the underlying mechanism of loss of function. This 
type of tumor development is called microsatellite mutator phenotype and has also been 
described in gastric cancer by several authors [2,3]. The other type of tumor development 
based on chromosomal imbalances is the chromosomal/ intrachromosomal instability type 
leading to amplifications and deletions of whole chromosomes as well as chromosome 
cytobands potentially harbouring tumor suppressor genes or oncogenes. The following 
locations have been observed to be frequently amplified in gastric cancer: 3p22, 4q25, 8q24, 
11p13, and 20q13. Losses have been documented most commonly at 1p36 and 9p21 [4]. 
Furthermore, it has been reported that intestinal type gastric cancer according to Lauren´s 
classification has a higher degree of chromosomal aberrations than the diffuse type. 
Furthermore, a relationship between clinical outcome and the degree of chromosomal 
aberrations in intestinal type gastric cancer was observed [5].  
Another level of chromosomal assessment is the detection of gross chromosomal imbalances 
by using flow cytometry. The loss or amplification of complete chromosomes is known to be 
a frequently occurring event in cancer development [6]. Non-diploid status of chromosomes 
has been shown to be present in about 20% of gastric cancer cases. Patients with a non-
diploid chromosome status have a significantly poorer survival than those who present with 
a diploid status [1]. 
Additionally, there is a growing body of evidence that the epigenetic level of regulation of 
gene expression plays an important role in cancer development. The chromatine 
remodelling machinery contains in particular enzymes that modify histons [7]. Recently, it 
has been shown that the histone demethylase RBP2 is upregulated in gastric cancer and that 
depletion of that enzyme causes senescence of resident tumor cells [8]. 
3. Hereditary gastric cancer 
In 10% of all gastric cancer cases, a familial clustering of the disease can be observed but 
only 1 -3% are of hereditary origin. In those cases where no histological finding is available 
the term “familial gastric cancer” is used [9]. The following syndromes include patients with 
available histology and are known to be associated with both familial clustering and certain 
germline mutations: hereditary diffuse gastric cancer, familial diffuse gastric cancer and 
familial intestinal gastric cancer. Furthermore, there are several syndromes which may 
include early onset gastric cancer in addition to other tumor manifestations: Lynch 
syndrome, Li-Fraumeni syndrome, Li-Fraumeni-like syndrome. Peutz-Jeghers syndrome 
and the familial adenomatous polyposis (FAP). 
Hereditary diffuse gastric cancer develops from germline mutations in the CDH-1 gene 
(about one third of cases) coding for E-cadherin, an important cell adhesion molecule on the 
lateral surface of the cellular membrane, whereas in two thirds of the cases the underlying 
mutation cannot be identified [9,10]. The inactivation of the CDH-1 gene may be triggered 
by epigenetic mechanisms (hypermethylation of the promoter region) as well as by a genetic 
mechanism (loss of heterocygosity plus CDH-1 mutation). The syndrome is associated with 
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early onset and gastric cancer lesions growing in multiple locations as well as with lobular 
breast carcinoma. The International Gastric Cancer Linkage Consortium defined two main 
criteria to identify patients susceptible for hereditary diffuse gastric cancer from the 
population: 2 cases of diffuse gastric cancer in first or second degree relatives (at least one of 
them to be younger than 50 years at the time of diagnosis) or 3 cases of diffuse gastric cancer 
in first or second degree relatives independently of the age at the time of diagnosis. Families 
with numerous cases of diffuse gastric cancer who do not fulfil these abovementioned 
criteria are considered to be familial diffuse gastric cancer [11]. 
The majority of cases of familial intestinal gastric cancer is associated with Lynch syndrome 
which is also termed hereditary non-polyposis colorectal cancer (HNPCC) [12,13]. 
Therefore, Caldas and co-workers suggested to identify patients with risk for familial 
intestinal gastric cancer by using the HNPCC-related Amsterdam criteria in countries with a 
high incidence of gastric cancer. In contrast, countries with a lower incidence should use the 
criteria analogous to hereditary diffuse gastric cancer [13]. 
Lynch syndrome is caused by germline mutations in genes associated to the mismatch 
repair (MMR) machinery. Most frequently, alterations of the MLH gene family (MutL-
homolog) or the MSH gene family (MutS-homolog) are responsible for the defective MMR. 
These two proteins form heterodimers that recognize mismatched bases selectively within 
the newly synthesized daughter DNA strand which can be removed subsequently by 
exonucleases. Appoximately 5 – 8% (depending on gender and the mutated gene) of 
patients with Lynch syndrome develop gastric cancer during their life time [12,14]. 
The Li-Fraumeni syndrome as well as the Li-Fraumeni-like syndrome originate from 
germline mutations of the TP53 gene. About 250 different mutations of that gene have been 
identified to cause a broad variety of tumor diseases, the majority of them being missense 
mutations leading to a molecule that cannot bind to the DNA [15]. There is a broad variety 
of tumor diseases which can develop based on that syndrome including breast cancer, 
adrenal tumors, sarcomas and gastric cancer. The Li-Fraumeni syndrome and the Li-
Fraumeni-like syndrome are distinguished by several clinical based criteria. Recently it has 
been demonstrated that the DNA repair gene BRCA2 might be another molecular 
mechanism of causing these syndromes [16]. 
Peutz-Jeghers syndrome (STK11 gene, coding for serin-threonin kinase 11) and the FAP 
(associated to the APC gene) can are associated with gastric cancer in rare cases. 
4. Dysregulation of signalling pathways 
Non-hereditary gastric cancer has a complex and multistep carcinogenesis in which – 
among numerous other factors – signalling pathways are involved. The dysregulation of 
these signalling pathways may lead to activation of genes that code for proteins regulating 
growth processes, such as cell division, differentiation, epithelial-mesenchymal transition 
and proliferation. Several studies on the molecular development as well as the progression 
of gastric cancer show clearly that there are differences in the biological behavior between 
young and elderly people. According to the classification of Lauren, intestinal gastric cancer 
with differentiated glandular growth pattern presents with a profile of dysregulated 
signalling pathways that can be distinguished from the diffuse type gastric cancer. 
Furthermore, there appears to be a difference between cancer of the upper stomach as 
compared to that of the lower stomach. 
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4.1 Tyrosine kinase signalling 
4.1.1 The epidermal growth factor receptor (EGFR) family and downstream signalling  
Epidermal growth factor receptor is a member of the ErbB receptor family and normally 
regulates gastric mucosa proliferation. Under normal conditions, two receptor molecules 
form dimers as a result of ligand binding and phosphorylate each other via their tyrosin 
kinase activity. Every heterodimer has its own effector molecule (see Fig. 1). One important 
pathway is the activation of the guanine exchange factor SOS which subsequently activates 
the MEK-ERK MAP kinase pathway leading to the expression of proliferation-promoting 
transcription factors, such as AP-1, ELK-1 and c-fos. Alternative signal transduction 
pathways downstream of the EGF receptor family are STAT and PKB (protein kinase B). An 
important downstream effector of PKB is the mTOR complex 1. Active mTOR complex 1 
leads via expression of specific mRNA stabilizing proteins and of ribosomal subunit S6 to 
increased proliferation. 
In summary, EGFR related signals promote many cellular activities towards tumor growth, 
in particular proliferation, migration, adhesion, apoptosis and differentiation [17]. 
 
 
Fig. 1. The members of the EGF receptor family and their typical ligands 
Dysregulation of signalling pathways downstream of the EGFR is frequently observed in 
gastric cancer. Therefore, currently two main subgroups of targeted drugs exist: first the 
inhibition of the receptor by blocking the ligand binding site and second the inhibition of the 
intracellular tyrosin kinase activity of the receptor molecule. For the first-mentioned 
mechanism the monoclonal antibodies cetuximab, matuzumab and panitumumab have 
been developed. Gefitinib and erlotinib are tyrosin kinase inhibitors. 
The ErbB2 receptor (Her2/Neu) can dimerize without a binding ligand and, thus, cannot be 
inhibited by antibodies against the ligand binding site. About one third of all tumors express 
ErbB2. In up to 27% of gastric cancer cases an overexpressed ErBB2 can be detected [18]. 
ErbB2 is overexpressed more frequently in intestinal type gastric cancers as compared to 
diffuse type gastric cancer. Furthermore, younger patients show less frequent ErbB2 
overexpression than elderly patients [19]. The humanized antibody trastuzumab inhibits the 
ErbB2 receptor and has been shown to provide a significant survival benefit in ErbB2-
positive cases [20].  
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Recently, it has been shown in vivo and in vitro on gastric cancer cell lines that the mTOR 
specific inhibitor rapamycin is effective in those cases which are resistant to EGFR 
inhibitors. Moreover, when administered in combination with cetuximab it can restore the 
anticancer effects of EGFR inhibition. Thus, rapamycin alone or in combination with other 
agents may provide a new target for the clinical use in the future [21]. 
K-ras, BRAF and SOS mutations are detected only in few gastric cancer cases [22]. 
Nevertheless the novel k-ras inhibitor tipifernib should be mentioned. K-ras mutations 
result in a continuosly active k-ras protein. Tipifernib inhibits the enzyme 
farnesyltransferase which forms an essential step in the posttranscriptional modification and 
thereby downregulates the k-ras signal. The clinical outcome of tipifernib administration in 
advanced gastric cancer is currently investigated in a phase 2 trial and might be a potential 
target-specific therapy for selected gastric cancer cases in the future, too [23]. 
4.1.2 Vascular endothelial growth factor (VEGF) and tumor angiogenesis 
When tumors grow larger than 1-2mm in diameter, further tumor growth requires the 
development of new blood vessels in the tumor environment. This tumor-related 
angiogenesis is different from physiological angiogenesis in terms of distinct vessel 
architecture, vascular permeability as well as a different interplay between endothelial cells 
and perivascular cells. One of the most potent angiogenesis-promoting factors is VEGF. 
VEGF is expressed as a result of tissue hypoxia. It promotes its biological effects (inhibition 
of apoptosis and proliferation of endothelial cells, increased endothelial cell migration) via 
binding to the VEGF receptor. Synchronously with the once initiated tumor angiogenesis the 
development of metastases is promoted. 
Overexpression of VEGF has been reported in gastric cancer cases. 
Currently, 4 different mechanisms of VEGF signalling inhibition can be distinguished: 
VEGF-inhibiting antibodies (bevacizumab), soluble VEGF receptors (aflibercept), VEGFR-
inhibiting antibodies (IMC-1121B) and VEGFR tyrosin kinase inhibitors (vatalinib, cediranib, 
sunitinib, sorafenib). 
To date, for gastric cancer no angiogenesis-inhibiting agent has been approved worldwide. 
But a growing experience with angiogenesis-inhibiting agents in colorectal cancer 
demonstrates a survival benefit with acceptable adverse effects [24]. 
4.1.3 Hepatocellular growth factor (HGF) and gastric cancer 
HGF signals induce a broad variety of biological features, such as morphogenesis, adhesion, 
migration, remodelling of extracellular matrix and are also involved in tumor angiogenesis 
[25]. It is known to be one of the key players in tissue regeneration following injury. Under 
physiological conditions, HGF is secreted in a paracrine manner most commonly by 
mesenchymal cells. Its target, the HGF receptor (HGFR or MET) is usually present on the 
surface of epithelial cells. Several cytokines, such as interleukin-1 and -6, tumour necrosis 
factor-┙ and transforming growth factor-┚ (TGF┚) that are released into the reactive 
interstitium (wound healing, cancer) induce the upregulation of HGF and HGFR expression. 
Furthermore, HGF is a strong antagonist of liver fibrosis by inhibiting the TGF┚ signal as 
well as by pro-apoptotic effects on myofibroblasts. [26]. Intracellular signal transduction is 
similar to the EGFR signalling pathways. 
In gastric cancer, the upregulation of the HGF signalling is an event which predominantly 
occurs at advanced stages, in particular in those who have liver metastases [27]. About 23% 
of patients with gastric cancer have an overexpression of c-met [28]. 
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There are currently no substances available for clinical use that inhibit the HGF signalling 
pathway but the effect of the novel agent XL880 (a tyrosin kinase inhibitor) on poorly 
differentiated gastric cancer is currently investigated. Furthermore, antibodies against HGF 
and MET are planned [29]. 
4.1.4 Fibroblast growth factor and its receptor FGFR in gastric cancer 
Like EGFR and HGFR, the fibroblast growth factor receptor belongs to the large family of 
receptor tyrosin kinases. To date, 23 different isoforms (FGF 1-23) and 4 receptor subtypes 
(FGFR 1-4) have been identified. FGFR2 or k-sam has been reported to be overexpressed in 
poorly differentiated gastric cancer The MAP-kinase pathway, the AKT pathway as well as 
NFAT signalling and activation of protein kinase C are the most prominent subsequent 
intracellular transduction pathways. Recently it has been shown that the receptor of 
keratinocyte growth factor on epithelial cells is identical with FGFR2. The amplification of 
the k-sam gene has been detected in poorly differentiated diffuse gastric cancer in about 
50% of cases resulting in a poor prognosis [30,31]. In contrast, it is rarely present in intestinal 
type gastric cancer. 
The novel FGFR2 inhibitor Ki23057 showed considerable antiproliferative effects in the 
mouse model and might become an effective target-specific agent in the future. 
4.1.5 Vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF) 
and its receptor PDGFR in gastric cancer 
VEGF and PDGF are key players of angiogenesis. Whereas VEGF promotes 
neoangiogenesis, PDGF has its impacts on the maintainance of microvessels. Both factors are 
secreted by tumor cells and act on the surrounding tumor microenvironment. There are 
protein families for both factors, the most important subtypes in gastric cancer are VEGF-A 
and PDGF-B. The signals are mediated via binding to VEGF- and PDGF receptors which 
have an autophosphorylating tyrosin kinase activity and subsequently initiate intracellular 
signal cascades that result in migration, proliferation and angiogenesis. 
The overexpression of both signal molecules has been shown to be correlating to each 
other in gastric cancer. PDGF-B seems to play a more important role in intestinal type 
gastric cancer whereas VEGF-A is more important for angiogenesis in diffuse type gastric 
cancer [32]. 
The PDGF receptor can be inhibited by imatinib. Imatinib is a specific tyrosin kinase 
inhibitor that is frequently used in gastrointestinal stroma tumors. A potential treatment 
option in the future might be the novel multiple receptor tyrosine kinase inhibitor 
LY2457546 which has been shown to have anti-tumor effects in animal models recently.[33] 
4.2 Proteinase-activated receptors (PAR) in gastric cancer 
Proteinase-activated receptors belong to the family of G-protein coupled receptors. The 
receptor is activated by serin-proteases, such as thrypsin and thrombin by removing an N-
terminal segment on the extracellular space. The thus created neo-N-terminal end 
subsequently serves as an intramolecular ligand that binds to the binding domaine. The 
signal  is then transferred to the intracellular space leading to activation of several signal 
transduction pathways. In gastric cancer cell lines, PAR2 has been shown to trans-activate 
the EGF receptor. This effect could not be blocked by EGFR inhibitors [34]. To date, there are 
no inhibitors of PAR evaluated for clinical use. 
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4.3 WNT signalling and the involvement of E-caherin 
The WNT signalling pathway belongs to the most important signalling systems and is 
evolutionary highly conserved. It plays a central role in embryonic differentiation processes. 
In adults, WNT activity can be detected within the stem cell niche of the gastrointestinal 
tract. Furthermore, there is a growing body of evidence that the WNT signalling pathway is 
a key player in the progression of tumors. The signal originates in the extracellular space 
with the binding of WNT (several subtypes exist) to its receptor frizzled. In co-operation 
with the co-receptor LRP the signal is  then transduced to the intracellular space. From here, 
4 different signalling cascades can be activated, which is shown in more detail in Tab. 1. In 
the classical or canonical WNT pathway the WNT signal leads to the destabilization of the 
multiprotein complex consisting of Axin, GSK3B and APC. GSK3b normally phosphorylizes 
beta catenin which in turn leads to the degradation of beta catenin. Intact beta catenin 
moves to the nucleus and binds to TCF/ LEF complex which constitutes a transcription 
factor with the subsequent expression of specific genes. 
 
WNT sub-pathway Targets Biological effects 
Canonical WNT/ beta catenin 
pathway 
Cyclin D1, c-myc, 




WNT/JNK Pathway = planar 
cell polarity pathway (PCP) 
Cytosceleton Cytosceletal remodelling, cell 
polarity 
WNT/ calcium pathway PKC, PLC Cell adhesion 
Asymmetric cell division 
pathway 
Mitotic spindle Asymmetric cell division 
Table 2. Several pathways downstream to the WNT signal 
It is of importance to know that the WNT signalling pathway is part of a complex network 
of signal transduction which is controlled and regulated by a multitude of factors belonging 
to different pathways. In particular, a complex crosstalk between WNT, E-cadherin and 
beta-catenin has been described. E-cadherin inhibits dimerisation and activation of the 
EGFR via binding to EGFR monomers. On the other hand, activation of EGFR leads to the 
internalization of E-cadherin-beta-catenin complexes which in turn induces expression of 
WNT dependent target genes [35].  
About 30% of gastric cancer cases show an overexpression of beta-catenin which is 
associated with poorer prognosis than beta-catenin-negative gastric cancer. The loss of APC 
function which is essential for the beta-catenin degradation is observed in about 20% of 
gastric cancer cases. The downregulation of SFRP – an inhibitor of the WNT receptor – by 
methylation of the promoter region has been described to occur in gastric cancer, too [17,36]. 
To date, there are no WNT specific anticancer drugs available. Recently, it has been 
demonstrated that differentiation-inducing factors downregulate the WNT pathway by 
activating the GSK3B in several cancer cell lines [37]. 
4.4 Sonic hedgehog signalling pathway (SHH) 
The basic structure of SHH shows some similarity with the WNT pathway: An extracellular 
ligand (SHH) binds to a receptor at the cell surface (patched) which transduces the signal 
into the cell. Thereby, an intracellular signal transducer (smoothened) is activated which in 
turn deactivates a multiprotein complex (fused, suppressor of fused, coastal and others). 
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This deactivation leads to accumulation of a nuclear factor (Gli) which is normally degraded 
by the functional multiprotein complex. Eventually, specific genes encoding proteins, such 
as cyclin D2, patched and Gli (positive feedback) are activated. There is a ample crosstalk 
with other signalling pathways, in particular the expression of TGF-beta (TGF-beta 
pathway), the expression of SFRP1 (WNT pathway) and FOXL1 (bone morphogenic 
pathway).  
The sonic hedgehog signalling plays a central role in embryonic development and has been 
shown to be upregulated in a broad variety of malignant tumors [38]. The overexpression of 
both Gli and the receptor patched have been reported in two thirds of gastric cancer cases. It 
has been shown that SHH expression is stronger in intestinal type gastric cancer and tubular 
growth pattern than in diffuse type gastric cancer and mucinous or undifferentiated growth 
pattern [39]. SHH is also overexpressed in non-malignant lesions, such as gastric adenomas 
or intestinal metasplasia. Due to the upregulation of SHH signalling at an early stage of 
cancer development it might serve as an early diagnostic tool in patients who have an 
increased risk for the development of gastric cancer. 
The SHH signalling pathway theoretically could be blocked by cyclopamine. This substance 
was first discovered on sheep that fed on a certain lilieaceous plant (veratrum californicum) 
and delivered lambs with only one eye, reflecting the crucial role of SHH in the 
differentiation of embryonic body axes. Currently the design of a fully synthetic 
cyclopamine analogon is underway. Another potential inhibitor of SHH signal might be 
HMG reductase inhibitors, such as statins. HMG reductase inhibitors are necessary to 
process the functional SHH molecule. To date, there are no studies available on the effect of 
statin-dependent downregulation of SHH signals by statins and its effects on clinical 
outcome in the field of gastric cancer. 
4.5 Notch signalling pathway and gastric cancer 
Notch signalling belongs to the morphogenic embryonic signalling pathways. Notch is 
involved in the regulation of cellular proliferation, apoptosis and differentiation. It 
participates in organ development and mediates lateral inhibition of neighboring cells. The 
receptor (notch) and its activating ligand (delta) are located on the cell surface of two 
different cells. The binding of delta to its receptor notch leads to a two-step cleavage of the 
receptor. The intracellular receptor residue then moves to the nucleus where it forms a 
complex with other proteins and in turn promotes specific gene expression. Notch-specific 
target genes encode for several members of the Hes-family (regulation of embryonic 
neurodermal development), CD 25 (interleukin receptor 2, parts of the T-cell receptor), 
GATA3 (transcription factor for T-cell maturation), c-myc, cyclin D1, p21 bcl-2 [40-46]. 
Upregulated notch signalling by the ligand Jagged1 has been reported to occur frequently in 
gastric cancer. This upregulation was associated with poorer survival. To date, there is no 
target-specific treatment introduced in the current literature.  
4.6 The transforming growth factor beta (TGFbeta)/ bone morphogenic protein (BMP) 
family and signalling pathways in gastric cancer 
TGFbeta-signalling is another member of the family of embryonic developmental pathways. 
In cancers, TGFbeta signalling has a bivalent function: at an early tumor stage it serves as a 
tumor suppressor by inhibiting proliferation and promoting cellular differentiation as well 
as apoptosis. These processes are regulated via theRunx3 and the SMAD4 protein [17]. 
www.intechopen.com
 
Molecular Features and Their Clinical Implications on Gastric Adenocarcinoma 
 
79 
During cancer progression, the corresponding genes are silenced by methylation or 
otherwise undergo loss of function. The tumor suppressive function changes dramatically in 
advanced tumor stages where BMP promotes tumor angiogenesis, cell motility and the 
interaction of tumor cells with the interstitium. Furthermore, the immune response is 
suppressed by BMP [47,48]. The tumor promoting function is realized via several MAP 
kinase signalling pathways. 
Similarly, BMP signals have bivalent functions: whereas BMP is upregulated in gastric 
inflammation it is downregulated in gastric cancer. On the other hand, BMP2 has been 
shown to promote tumor cell motility and, thus, invasiveness of gastric cancer. Furthermore, 
activins that constitute another subgroup of the TGFbeta/ BMP superfamily have tumor 
suppressive effects via activation of several caspases (pro-apoptotic),  activation of p21 (cell 
cycle arrest) and downregulation of bcl-2 (anti-apoptotic) [49]. In summary, TGFbeta, BMP 
and activin signals can be regarded as a tumor suppressive mechanism restricted to certain 
stages of tumor progression [17]. 
In scirrhous gastric cancer cell lines it has been observed that treatment with two novel 
TGFbeta receptor 1 inhibitors (Ki26894 and A-77) decreases biological tumor progression 
features, such as invasiveness and epithelial-mesenchymal transition. These compounds are 
potential targeted drugs for metastatic scirrhous gastric cancer in the future [17,50,51]. 
4.7 Cell cycle dysregulation in gastric cancer 
The cell cycle is strictly regulated by a broad variety of controlling factors. To move the cell 
cycle machinery forward, several checkpoints that control the entry to the next cell cycle 
phase have to be passed [52]. The most important checkpoint is the G1/S-checkpoint which 
regulates the initiation of cell division [53]. Under physiological conditions growth factors 
and other signals are needed to open the gate but in cancer cells the cell cycle can be active 
without the presence of activating signals and furthermore might be accelerated by 
overexpressed growth factors as mentioned above. Figure 2 illustrates the different 
checkpoints as an overview. 
Both cyclin D and E in combination with the corresponding cyclin dependent kinase CDK 
4/6 and CDK2 are essential for the S phase entry and the subsequent activation of the 
retinoblastoma protein [54]. Both cyclin D1 and 2 are known to be frequently upregulated in 
gastric cancer [17,54]. Cyclin D subtypes are downstream targets of several signalling 
pathways (Notch, SHH, WNT) whereas cyclin E has been reported to be upregulated by 
gene amplification in about 15% of gastric cancer cases [55]. 
The TP-53 tumor suppressor gene is due to its various functions also called the “guardian 
of the genome”. The protein p53 recognizes signals that point to DNA damage, initiates 
cell cycle arrest for damage repair (by activating target genes that encode for p21), 
functions as a transcription factor that activates expression of DNA repair genes and also 
can promote cell death via apoptosis in cases of irreparable DNA damage [56]. About 50% 
of all tumors and 40% of gastric cancer cases present with TP-53 mutations resulting in a 
loss of p53 function. Loss of p53 is frequently associated with advanced tumor stages and 
undifferentiated tumors reflecting the increased accumulation of mutations within the 
tumor cell genome [57]. 
The loss of function of the tumor suppressor p21 occurs in 60% of gastric cancer cases and is 
associated with increased invasiveness, metastasis and poor prognosis. Moreover, the 
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incidence of that loss increases with advancing tumor stages. The p27 which is an inhibitor 
of the CDK4-cyclinD complex and the CDK2-cyclinE complex as well arrest the cell cycle at 
the restriction checkpoint [58]. The loss of p27 similarly to p21, occurs in gastric cancer in 
dependence of tumor stage and predicts poor prognosis [59].  
 
 
Fig. 2. Checkpoints of cell cycle 
4.8 Nuclear factor kappa B in gastric cancer  
Nuclear factor kappa B (NFkappaB) is a quick-time transcription factor that modulates the 
immune reaction and regulates proliferation and apoptosis. Extracellular signals 
(interleukin 1beta, tumor necrosis factor alpha via their receptors) as well as free radicals, 
bacterial and viral antigens are transmitted to the nucleus within minutes. This is 
accomplished by storing NFkappaB bound to a complex (IkappaB) in the cytoplasma from 
which NFkappa B is mobilized via inactivation of IkappaB by a IkappaB specific kinase 
(IKK). The free NFkappaB molecule can then move within the nucleus and activate specific 
genes like cytokines (IL-6, IL-1beta, TNF), chemokines (IL-8, CCL2, CCL3), enzymes (iNOS, 
COX-2) and adhesion molecules (VCAM-1, ICAM-1, CEACAM-1) which in turn promote 
inflammatory processes [60]. 
NFkappaB plays a central role in inflammatory cancers. Dysregulation of the NFkappaB has 
been observed in gastric cancer to be associated with increased proliferation, genomic 
instability and drug resistance [61,62]. 
There is a variety of phytochemicals, such as silibinin, resveratrol and catechins which are 
known to suppress the activation of NFkappaB. Also, several poly-phenol bonds (green tea) 
can act as anti-cancer drugs. Furthermore, inhibitors of IKK are studied at a preclinical 
stage [60].  
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4.9 S-100 proteins in gastric cancer 
The S-100 protein family currently counts 21 members which are responsible for various 
cellular functions, in particular they are assumed to be second messenger molecules which 
interact with numerous different molecules. S-100A2, 3, 4, 7 and 10 have been observed to be 
overexpressed in gastric cancer.  
S-100A4 is regulated by epigenetic mechanisms and by beta-catenin. Overexpressed S-100A4 
was associated with advanced tumor stages, diffuse type gastric cancer and increased 
incidence of tumor lymph node involvement [63]. S-100A4 has been demonstrated to be 
upregulated predominantly in early stages of gastric cancer [64], other studies associated 
this protein to metastasis in several tumors and, therefore, it is also named metastasin. S-
100A4 has a multitude of binding partners, such as E-cadherin, p53, actin and p37 among 
many others. Interestingly, S-100A4 is one of the strongest molecular based predictors of 
survival in patients with ovarian carcinoma, pancreatic cancer and gastric cancer [65]. 
Moreover, calcyclin-binding protein has been shown to inhibit proliferation and 
invasiveness in gastric cancer by promoting S-100-protein ubiquitinylation which might be a 
potential target-specific treatment option in the future [66]. 
4.10 Dysregulated DNA repair mechanisms 
The accurate transfer of genetic information through the DNA replication and cell division 
machinery is dependent on both, exact DNA synthesis procedure and sufficient DNA 
damage repair systems. Moreover, the DNA is permanently  exposed to toxic metabolites, 
such as oxygen radicals and to physical stress, such as ultraviolet radiation. In addition, 
spontaneous mutations and DNA methylation occur. In particular, 4 basic mechanisms of 
DNA repair exist: 1.) the single base excision system, 2.) mismatch repair system, 3.) the 
nucleotide excision repair system and 4.) the double strand break repair system. 
The single base excision system removes defective and modified bases. Therefore, two 
mechanisms exist: either the aberrant base is recognized and selectively removed by specific 
DNA glycosylases resulting in an apurinic or apyrimidic ribosyl residue which is in turn 
cleaved by a AP endonuclease; or the base is repaired directly without removing. 
The mismatch repair system recognizes mismatched single bases, small single strand loops 
and the recombination of non-homologous sequences. Heterodimers from MLH2, 3 and 6 
recognize and bind to those DNA loci which in turn leads to the recruitment of further 
proteins (helicase, single strand binding protein, MSH, and others) forming a protein 
complex. Hereditary defects in this system are known as as the Lynch syndrome. 
The nucleotide excision repair system in particular is responsible for recognizing and 
repairing DNA damage that is caused by solar radiation. As a logical consequence those 
patients who have genetic defects concerning this system primarily present with dermal 
diseases due to the direct exposition of the skin to solar radiation (e.g. xeroderma 
pigmentosum). It is the only one repair system that is able to remove bulky adducts (dimers 
of pyrimidin and cyclobutan) and remove up to 32 nucleotides. More than 30 genes are 
involved in that repair mechanism system.  
The double strand break repair system can either act with homologous recombination (HR) 
immediately behind the replication fork or can act with non-homologous endjoining 
(NHEJ). The first mechanism requires a sister chromatide which is not available during G0 
and G1 phase, therefore in these phases of cell cycle only NHEJ can be performed. The 
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Defective DNA repair systems cause the accumulation of mutations which can lead to 
transformation provided that the mutation provides a selection benefit. Therefore, it is not 
surprising that genetic defects in DNA repair are associated with the development of 
malignant tumors, as it is the case in about 15% of all colorectal cancer cases as well as in 
other tumor entities like ovarian carcinoma and endometrial carcinoma. For gastric cancer it 
has been reported that about 8% of sporadic cases show microsatellite instability pointing to 
defective DNA mismatch repair [69]. 
PARP inhibitors which block the enzyme poly(ADP-ribose) polymerase might a become 
potential target specific therapy in cases of mutated BRCA1 and 2. The substance psoralen 
that induces interstrand crosslinks is investigated in preclinical studies [67].  
5. Conclusion 
A growing body of knowledge about the biological behavior as well as the molecular nature 
of gastric cancer is available in the current literature. Although there are only few targeted 
treatment strategies implemented in the clinical routine a large number of studies dedicated 
to molecular based strategies is currently underway. 
This chapter also implicates that there is a complex pattern of molecular mechanisms that 
extend the interpretation of gastric cancer in addition to classifications that are exclusively 
based on macroscopic and histological findings. The pattern of genetic imbalances and of 
dysregulated pathways is of essential importance to treat patients in a more individualized 
fashion. 
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